Availability: TB-500 is not currently orderable from Rebody. This guide separates the fragment from thymosin beta-4 research; it does not present either as a current Rebody product.
The short answer
TB-500 and thymosin beta-4 have separate evidence records: one is a seven-amino-acid fragment, the other a 43-amino-acid protein.
Options at a glance
| Substance | Identity | Closest evidence | Critical boundary |
|---|---|---|---|
| TB-500 | Acetylated seven-amino-acid fragment | Direct laboratory work | Own fragment evidence record |
| LKKTETQ fragment | Non-acetylated seven-amino-acid sequence | Migration and aged-mouse wound work | Own sequence and acetylation state |
| Thymosin beta-4 | 43-amino-acid parent protein | Wound, migration, and human development programs | Own parent-protein evidence record |
What belongs in this category
Actin signaling, cell migration, angiogenesis, and wound repair are research mechanisms, not interchangeable product outcomes. The first comparison is molecular identity: seven amino acids, acetylation state, or the full 43-amino-acid parent protein.
TB-500 belongs in this category because it is marketed around the actin-binding region. Its useful claims begin with the fragment studies themselves, while “systemic healing” remains too broad to describe a measured endpoint.
What these molecules are
TB-500 commonly refers to an acetylated seven-amino-acid sequence related to residues 17–23 of thymosin beta-4. Thymosin beta-4 itself contains 43 amino acids. Published fragment work may use non-acetylated LKKTETQ, adding another identity difference.
Parent protein, fragment, and finished vial must remain separate in every claim. A study belongs to the substance actually tested, at the route and concentration actually used.
What the research measured
Aged-mouse wound research tested full thymosin beta-4 and a non-acetylated LKKTETQ fragment, with wound closure and tissue measures. Other laboratory programs examined cell migration, actin-related behavior, or angiogenic responses. These studies explain the mechanism category.
The direct TB-500 record is narrow. FDA's review identified no human exposure, pharmacokinetic, safety, or efficacy study for TB-500, and a fibroblast scratch assay at the tested condition found no significant wound-closure difference from vehicle.
Human thymosin beta-4 wound studies answer questions about the 43-amino-acid protein at their specific routes. TB-500 keeps the separate record of the acetylated seven-amino-acid fragment.
Which option wins this comparison
TB-500 wins the exact fragment category when its identity is verified. Full thymosin beta-4 wins the parent-protein development record. Keeping those records separate makes the comparison useful.
The strongest mechanism claim names the substance, model, route, duration, and endpoint. A finished vial earns that evidence by matching the tested identity.
Strength, concentration, and dose are different facts
Cell-culture concentrations, animal wound protocols, and a human injection prescription cannot be converted by matching milligrams. Molecular form, absorption, route, and endpoint all differ.
Use only the final label for concentration, injection volume, amount per use, and frequency. Do not derive a TB-500 schedule from a thymosin beta-4 paper or a non-acetylated fragment experiment.
What the routine changes in real life
A mechanism does not tell someone how often to inject. The routine must come from the finished prescription and include clean handling, site rotation, sharps disposal, storage, travel, and refill timing.
Track a concrete functional or wound outcome rather than “systemic healing.” Photographs, surface area, drainage, pain, load tolerance, and clinician-defined milestones are more interpretable than a broad recovery score.
Storage, shipping, and travel
Stability belongs to the finished substance and formulation. Do not assign full thymosin beta-4 storage instructions to TB-500 or assume an acetylated and non-acetylated fragment behave identically.
Follow the label, keep the lot and beyond-use date, avoid freezing and excess heat, and hold any cracked, leaking, cloudy, particulate, or discolored vial for pharmacy guidance.
Side effects and urgent symptoms
The lack of identified human TB-500 exposure data means systemic risks are not characterized. Injection adds pain, bruising, bleeding, contamination, and infection risks. A hot spreading area, drainage, red streaking, fever, facial swelling, trouble breathing, or fainting needs prompt help.
Human safety observations for full thymosin beta-4 cannot be transferred wholesale to a different fragment. Tested athletes must also account for current anti-doping rules.
Price, supply, and refills
Do not pay a premium for a parent-protein claim attached to a fragment vial. Value begins with verified molecular identity, concentration, prescribed supply, storage, and a measured outcome.
The least expensive product is still poor value when its label is ambiguous or its marketing depends on studies of a different substance.
Questions people ask before starting
Can I take BPC-157 and TB-500 every day?
Use the exact schedule printed on the prescription label. TB-500 and BPC-157 have different identities and historical schedules, so parent-protein experiments, fragment mechanism studies, and online stacks do not set the cadence.
What are the risks of taking TB-500?
FDA's review identified no human TB-500 exposure, pharmacokinetic, safety, or efficacy study. Injection risks include pain, bruising, contamination, and infection, and TB-500 is prohibited for tested athletes. Human thymosin beta-4 safety observations belong to the 43-amino-acid parent protein.
Is TB-500 the same as thymosin beta-4?
No. TB-500 commonly refers to a seven-amino-acid fragment related to residues 17–23 of thymosin beta-4. Thymosin beta-4 is a 43-amino-acid protein, so its human wound studies cannot be presented as TB-500 trials. Keeping 7 and 43 amino acids separate is the central evidence rule for this cluster.
What changes between 5 mg and 10 mg vials?
Five and ten milligrams usually describe total active in the vial, not the amount used at one time. Concentration, prescribed dose, frequency, days of supply, price per day, and refill timing decide which package is more practical. Exact molecular identity comes first.
What did the strongest study measure?
The most relevant fragment evidence comes from aged-mouse wounds and laboratory migration or sprouting assays; full thymosin beta-4 and TB-500 must remain separate.
How do route and product form change the answer?
The direct TB-500 record is preclinical; human studies of full thymosin beta-4 belong to the 43-amino-acid parent protein.
What should happen after a missed dose?
Do not double the next dose. Note when it was missed and ask the care team or dispensing pharmacy whether to resume or shift the schedule; a missed dose is not a reason to improvise.
How should the product be stored for travel?
For this actin-fragment evidence comparison, travel with the product in its original labeled container and follow its exact temperature range. Protect it from freezing and direct contact with ice. After a warm shipment, leak, crack, broken seal, cloudiness, particles, or color change, hold the dose for guidance from the dispensing pharmacy; the finished formula controls the answer.
Why are TB-500 and thymosin beta-4 not interchangeable?
They differ in size and identity. TB-500 commonly refers to an acetylated seven-amino-acid fragment related to residues 17–23 of thymosin beta-4; the parent protein has 43 amino acids. Fragment studies may also use non-acetylated LKKTETQ. Acetylation, length, formulation, and route can change stability and biological behavior, so results remain attached to the substance tested.
What does the actin-binding region have to do with recovery claims?
It explains the research interest in cell movement, cytoskeletal behavior, angiogenesis, and wound models. Strong claims stay attached to those measured mechanisms, with the model, route, duration, comparator, and endpoint stated plainly.
Is there direct human TB-500 evidence?
FDA's review identified no human exposure, pharmacokinetic, safety, or efficacy study for TB-500 by any route. Human development involving full thymosin beta-4 belongs to a different molecule, leaving TB-500 with a narrower preclinical record.
What would a convincing TB-500 study need to report?
It would identify the exact seven-amino-acid substance and formulation, enroll a defined human population, use a stated route and schedule, include a meaningful comparator, and measure prespecified clinical outcomes over a clear duration. Pharmacokinetics and adverse events would also matter. A mechanism assay or parent-protein trial cannot answer all of those questions.
Parent protein and fragment are different evidence records
Read this literature in two columns. In the thymosin beta-4 column, record studies using the full 43-amino-acid protein, including route and wound context. In the TB-500 column, record the exact short sequence, acetylation state, model, and endpoint. Molecular relation motivates experiments, while distribution, stability, potency, and clinical effects stay attached to the substance actually tested. The result is a developed parent-protein record and a narrower preclinical fragment record.
The label is the fastest identity test
A useful TB-500 comparison starts with four lines from the finished label: the exact active name, chemical form, concentration, and total fill. “Related to thymosin beta-4” is background, not an identity. A seven-amino-acid acetylated fragment, a non-acetylated LKKTETQ research reagent, and the full 43-amino-acid protein belong in three separate rows.
Then compare what the package makes possible: amount per prescribed use, usable days of supply, storage, beyond-use date, injection supplies, and cost per prescribed day. That catches the two biggest buying mistakes at once. It prevents a parent-protein study from being used as proof for a fragment vial, and it prevents a larger milligram number from masquerading as a better package. The strongest choice is the product whose identity is explicit and whose usable supply fits the actual prescription.
Bottom line
TB-500 and thymosin beta-4 have separate evidence records: one is a seven-amino-acid fragment, the other a 43-amino-acid protein.
Keep reading
- Actin-Signaling Peptides for Tissue Recovery Research
- Prescription Peptide Injections vs laboratory-only Vials
- Peptides Studied in Wound-Repair Models
Primary sources
- https://pubmed.ncbi.nlm.nih.gov/12581423/
- https://pubmed.ncbi.nlm.nih.gov/14500546/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list